High-Affinity, Structure-Validated and Selective Macrocyclic Peptide Tools for Chemical Biology Studies of Huntingtin
Esther WolfiD, Rebeka Cataldo de Oliveira FantiiD, Tatsuya IkenoueiD, Justin C. DemeiD, Swati BalakrishnaniD, Brandon A. Keith, Matthew G. AlteeniD, Renu ChandrasekaraniD, Manisha Yadav, Ritika BhajiawalaiD, Suzanne Z. AcklooiD, Feng JiaiD, Mahmoud A. PouladiiD, A.M. EdwardsiD, Derek J. WilsoniD, Susan M. LeaiD, Hiroaki SugaiD, Rachel HardingiD
Abstract
Huntingtons disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin (HTT) gene, with no disease-modifying therapies currently available. The precise molecular function of the HTT protein is unclear, and the lack of selective chemical tools has limited functional studies. We have identified and characterized macrocyclic peptide binders targeting HTT. These binders exhibit low-nanomolar affinity in vitro and engage distinct HTT and HTT-HAP40 interfaces, as revealed by hydrogen-deuterium exchange mass spectrometry and cryo-electron microscopy. Chemoproteomics confirmed selective binding in cell extracts from wildtype but not HTT-null cell lines. HAP40 consistently and stoichiometrically co-purified with HTT across cell lines, including with HTT variants containing different CAG repeat lengths, highlighting the broad presence of the HTT-HAP40 complex. Significance StatementHuntingtin (HTT) is a large, essential protein with conserved roles in development, intracellular trafficking, and protein homeostasis, yet its precise molecular functions remain incompletely defined. Here, we report the first high-affinity, selective, and structurally validated macrocyclic peptide ligands for HTT. These chemical tools bind HTT and its complex with HAP40 across polyglutamine repeat lengths, enabling direct interrogation of HTT structure and function in health and disease contexts. By overcoming longstanding barriers to studying HTT at the molecular level, these ligands open new avenues for discovery in neurobiology, cell biology, and offer opportunities for therapeutic development. This study delivers urgently needed tools to both the Huntingtons disease field and the broader scientific community seeking to understand this elusive and biologically fundamental protein.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Macrocyclic Peptide Tools for Huntingtin-bound HAP40
Esther Wolf, Rebeka Cataldo de Oliveira Fanti, … Rachel J. Harding·bioRxiv·Jun 2, 2026
- Identification and Characterization of a Small Molecule Ligand for the Huntingtin-HAP40 Complex
Rocher Leung, Esther Wolf, … Rachel Harding·bioRxiv·Nov 21, 2025
- Expanding the Huntingtons disease research toolbox; validated huntingtin subdomain constructs for biochemical and structural investigation of the huntingtin protein
M. G. Alteen, J. C. Deme, … R. J. Harding·bioRxiv·Nov 21, 2022
- HAP40 orchestrates huntingtin structure for differential interaction with polyglutamine expanded exon 1
R. J. Harding, J. C. Deme, … C. H. Arrowsmith·bioRxiv·Apr 2, 2021
- Highly Potent Peptide Therapeutics To Prevent Protein Aggregation In Huntington s Disease
Anooshay Khan, Cemile Elif Özçelik, … Urartu Özgür Şafak Şeker·ACS Medicinal Chemistry LettersPeer-reviewed·Nov 14, 2023
- Dual-reporter assay for selective small molecule inhibition of expanded toxic huntingtin
Elizabeth A Kraichely, Sungah Kim, … Peter Chung·bioRxiv·Nov 9, 2026